Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 113

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 113
---
.  |  Q3 2025 Form 10-Q  |  44

Results of Operations

Comparison of the Three and Nine Months Ended September 30, 2025 and 2024 

Revenues

Net product sales consist of sales of (i) EXPAREL in the U.S., E.U., and the United Kingdom, or U.K.; (ii) ZILRETTA in the U.S.; (iii) iovera° in the U.S., Canada, the E.U., and the U.K. and (iv) sales of our bupivacaine liposome injectable suspension product for veterinary use. Royalty revenues are related to a collaborative licensing agreement from the sale of our bupivacaine liposome injectable suspension for veterinary use.

The following table provides information regarding our revenues during the periods indicated, including percent changes (dollar amounts in thousands):

Three Months EndedSeptember 30,% Increase / (Decrease)Nine Months EndedSeptember 30,% Increase / (Decrease)2025202420252024Net product sales:EXPAREL$139,902 $132,004 6%$419,348 $401,286 5%ZILRETTA28,982 28,420 2%83,654 84,966 (2)%iovera°6,465 5,655 14%17,176 16,359 5%Bupivacaine liposome injectable suspension2,691 1,643 64%5,803 7,322 (21)%Total net product sales178,040 167,722 6%525,981 509,933 3%Royalty revenue1,476 851 73%3,557 3,780 (6)%Total revenues$179,516 $168,573 6%$529,538 $513,713 3%

EXPAREL revenue increased 6% and 5% in the three and nine months ended September 30, 2025 versus 2024, respectively. Components of the increase included a 9% and 6% increase in gross vial volume in the three and nine months ended September 30, 2025 versus 2024, respectively, partially offset by a shift in product mix and decreases in net selling price per unit in both the three and nine months ended September 30, 2025 versus 2024. The decrease